Business Standard

Concord Drugs Share Price

Know More

38.30-0.70 (-1.79%)

04:01 PM,18th Jul 2024
Stock not traded

BSE : 538965


Sector : Health care

ISIN Code : INE858L01010

  • BSE
  • 1D
  • 5D
  • 1M
  • 6M
  • 1Y
  • 2Y
  • 5Y
  • MAX

Last Updated: 18-Jul-2024 | 04:01 PM IST

Market Cap (₹ Cr)


Traded Value (₹ Cr)


Volume (Shares)


Face Value (₹)


52-Week High (₹)


52-Week High Date


52-Week Low (₹)


52-Week Low Date


All Time High (₹)


All Time High Date


All Time Low (₹)


All Time Low Date


Concord Drugs Ltd

Concord Drugs Limited established in 1995 is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals Dry Syrup powder) Tissue Bio-Adhesive tablets capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh Drugs Control Administration and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections Dry powder Injections and Ready-to-fill Pellets e...
Read More

Concord Drugs Announcement

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr><td>1</td><td>Name of Company</td><td>Concord Drugs Ltd</td></tr> <tr><td>2</td><td>CIN NO.</td><td>L24230TG1995PLC020093</td></tr> <tr><td>3</td> <td>Outstanding borrowing of company as on 31st March / 31st December as applicable (in Rs cr)</td> <td>149326835.84</td></tr> <tr><td>4</td><td>Highest Credit Rating during the previous FY </td><td>NA</td></tr> <tr><td>4a</td><td>Name of the Credit Rating Agency issuing the Credit Rating mentioned in (4)</td><td>Not Applicable</td></tr> <tr><td>5</td><td>Name of Stock Exchange# in which the fine shall be paid in case of shortfall in the required borrowing under the framework</td><td>BSE</td></tr> </table> <br/><br/> <div> <div style=float:left;> We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No</div> <br/><br/><br/> <div style=float:left;> Name of the Company Secretary: Namratha <br/> Designation: Company Secretary and Compliance officer <br/> EmailId:</div> <div style=float:left;margin-left:50px;> Name of the Chief Financial Officer: Kobi Reddy Seelan <br/> Designation: CFO <br/> EmailId:</div> </div> <div> <br/> Date: 21/05/2024<br/><br/> <b>Note:<b> In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. </div>

View More

Concord Drugs Ltd - Key Fundamentals

Market Cap (₹ Cr)


EPS - TTM (₹) [C]


P/E Ratio (X) [C]


Face Value (₹) 10
Latest Dividend (%)-
Latest Dividend Date -
Dividend Yield (%) -
Book Value Share (₹) [C]33.82
P/B Ratio (₹) [C]1.13

Funds Owning this Stock

Scheme Name Amount Invested (₹ Cr) No Of Shares Net Asset (%)

Research Reports

DateBrokerActionPrices(₹) Report
Data Not Found

Stock Strength

Today's Low/High (₹)



Week Low/High (₹)



Month Low/High (₹)



Year Low/High (₹)



All time Low/High (₹)



Share Price Returns

1 Week-0.83%%1.811.99%
1 Month-1.69%%5.235.28%
3 Month4.79%%12.2112.75%
6 Month-11.63%%14.2715.56%
1 Year42.49%%21.7825.58%
3 Year22.76%%53.0755.75%

Company Info

Company Information

Chairman & Managing Director : S Nagi Reddy

Independent Director : K Ramchandra Reddy

Whole Time Director & CFO : Koni Reddy

Independent Director : S. Nagavenkata Hareesh

Whole-time Director : S. Manoj Kumar Reddy

Independent Director : Summela Kasu

Company Sec. & Compli. Officer : Namratha Nagla

Registered Office: Survey No 249 Brahmanapally V, Hayathnagar M,Ranga Reddy,Telangana-501511 Ph: 91-40-24036379


FAQs about Concord Drugs Ltd

1. What's the Concord Drugs Ltd share price today?
Concord Drugs Ltd share price was Rs 38.30 at 04:01 PM IST on 18th Jul 2024. Concord Drugs Ltd share price was down by 1.79% from the previous closing price of Rs 39.00. Concord Drugs Ltd share price trend:

  • Last 1 Month: Concord Drugs Ltd share price moved down by 1.69% on BSE
  • Last 3 Months: Concord Drugs Ltd share price moved up by 4.79% on BSE
  • Last 12 Months: Concord Drugs Ltd share price moved up by 42.49% on BSE
  • Last 3 Years: Concord Drugs Ltd price moved up by 22.76% on BSE

2. How can I quickly analyse the performance of the Concord Drugs Ltd stock?
The performance of the Concord Drugs Ltd stock can be quickly analysed on the following metrics:

  • The stock's PE is 81.49
  • Price to book value ratio is 1.13
  • Dividend yield of 0.00
  • The EPS (trailing 12 months) of the Concord Drugs Ltd stock is Rs 0.47

3. What is the market cap of Concord Drugs Ltd?
Concord Drugs Ltd has a market capitalisation of Rs 38 crore.

4. What is Concord Drugs Ltd's 52-week high/low share price?
The Concord Drugs Ltd’s 52-week high share price is Rs 61.50 and 52-week low share price is Rs 25.56.

5. Is the Concord Drugs Ltd profitable?
On a consolidated basis, Concord Drugs Ltd reported a loss of Rs -0.35 crore on a total income of Rs 14.47 crore for the quarter ended 2024. For the year ended Mar 2024, Concord Drugs Ltd had posted a loss of Rs -0.34 crore on a total income of Rs 15.64 crore.

6. Which are Concord Drugs Ltd’s peers in the Health care sector?
Concord Drugs Ltd’s top 5 peers in the Health care sector are Veerhealth Care, Shree Ganesh Bio, Roopa Industries, Concord Drugs, Phaarmasia, Guj. Terce Labs., Panjon.

7. Who owns how much in Concord Drugs Ltd?
Key changes to the Concord Drugs Ltd shareholding are as follows:

  • Promoter holding in Concord Drugs Ltd has gone up to 55.41 per cent as of Mar 2024 from 53.83 per cent as of Oct 2023.